-
Sector Analysis
Hepatitis C Virus: Epidemiology Report and Forecast to 2035
Hepatitis C is an inflammatory liver disease caused by the hepatitis C virus (HCV). HCV primarily spreads through direct blood contact, which can happen via needle/syringe sharing in people who inject drugs, unscreened blood transfusions and unsterilized medical equipment, and sexual contact involving blood. Additionally, vertical transmission of HCV can occur (Public Health England, 2018). Many people with hepatitis C are asymptomatic and unaware that they have the infection, with only approximately a quarter of patients exhibiting symptoms, including fatigue,...
-
Sector Analysis
Epilepsy: Epidemiology Report and Forecast to 2035
Epilepsy is a neurological condition defined by repeated, unpredictable seizures resulting from abrupt, chaotic, and intense electrical activity among brain cells (World Health Organization, 2024a). Globally, it ranks as one of the most widespread neurological disorders (World Health Organization, 2024a). This chronic condition can develop at any point in a person's life. A diagnosis typically occurs after an individual experiences at least one seizure and sees a specialist, who evaluates detailed accounts of both the pre-seizure warning signs and the...
-
Company Insights
Catalyst Monitor: Q3 2026 Outlook
This report compiles published, predictive intelligence based on interviews with key opinion leaders (KOLs) on market-moving events that are expected to occur in Q3 2026. GlobalData’s latest report, “Catalyst Monitor Q3 2026”, delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, Phase III trial results, PDUFA dates, and regulatory filings. The report covers 11 significant catalyst events that are expected to occur in Q3 2026. Some of the catalysts covered in the report, include...
-
Sector Analysis
New Drug Approvals and Their Contract Manufacture: 2026 Edition
This report is the 16th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how the US onshoring push is creating billion-dollar manufacturing investments.
-
Thematic Analysis
State of the Biopharmaceutical Industry 2026 (Mid-Year Update) Edition
Report Value Proposition – Why This Matters for You The biopharmaceutical industry enters 2026 facing a rapidly evolving landscape shaped by artificial intelligence adoption, regulatory changes, pricing pressures, geopolitical uncertainty, and increasing competition for innovation leadership. This report helps stakeholders understand the trends that will define biopharma performance over the next 12 months, covering R&D productivity, commercialization strategies, market access challenges, investment sentiment, and emerging growth opportunities. Drawing on industry surveys, proprietary market intelligence, and expert analyst insight, the report...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, May 2026
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
Nasal Polyps (Nasal Polyposis) and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Nasal Polyps (Nasal Polyposis) and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps) Therapeutics. In 2025, there were more than 5.15 million diagnosed incident cases of nasal polyps and CRSwNP in the 16 countries covered in GlobalData’s epidemiology forecast. The current treatment landscape for nasal polyps primarily involves intranasal corticosteroids, oral corticosteroids for severe cases, and functional endoscopic sinus surgery for patients unresponsive to medical therapy, with biologics...
-
Sector Analysis
Chronic Kidney Disease: Epidemiology Report and Forecast to 2035
Chronic kidney disease (CKD), or chronic renal disease (International Classification of Diseases 10th Revision [ICD-10] code = N18), is a condition characterized by a gradual loss of kidney function over time. This leads to the accumulation of excess fluid and waste in the body. In the early stages, CKD is a largely asymptomatic condition. As the disease progresses, symptoms worsen and eventually lead to kidney failure (Centers for Disease Control and Prevention, 2024). Advanced CKD can lead to dangerous levels...
-
Sector Analysis
Male Infertility Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
Report Value Proposition – Why Does the Male Infertility Therapeutics Market Matter? Male infertility remains an important yet underserved therapeutic area, with growing attention on improving diagnosis, understanding disease mechanisms, and developing targeted treatment options. Although diagnosed prevalence is expected to remain relatively stable across the seven major pharmaceutical markets (7MM), significant unmet clinical needs and limited approved therapies continue to create opportunities for innovation and investment. GlobalData's Male Infertility Therapeutics Market Analysis provides a comprehensive assessment of the market...
-
Sector Analysis
Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Therapeutics. In 2025, there were more than 1.12 million diagnosed prevalent cases of PBC in the 16 countries covered in GlobalData’s epidemiology forecast. Currently, the PBC market is saturated with generic drugs and has a limited number of approved drugs available to treat PBC. The DR pipeline holds 32 molecules, with no assets in the pre-registration stage, four assets in...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.